title: Serological AFP/Golgi protein 73 could be a new diagnostic parameter of hepatic diseases.
abstract: We have investigated the changing rule of serum form of GP73 (sGP73) in different hepato-pathologic processes and identified the sGP73 role in inflammation, fibrosis and carcinogenesis since sGP73 has been regarded as a candidate tumor marker. Quantitative enzyme-linked immunosorbent assay detected sGP73 in 535 subjects with hepatocellular carcinoma (HCC), liver cirrhosis (LC), hepatitis, focal nodular hyperplasia (FNH), angioma, intra-hepatic cholangio-carcinoma (ICC) and metastatic cancer from adenocarcinomas (MC). Median sGP73 in LC was higher than in HCC and hepatitis (p = 0.001), and sGP73 in all three groups were higher than those in healthy individuals (p < 0.001); sGP73 in LC patients with Child-Pugh class A was lower than in class B and C (p = 0.001), no significant difference was found between early and advanced HCC groups (110.4 μg/L vs. 102.8 μg/L). AFP/GP73 had a sensitivity of 75.8% and specificity of 79.7% with an area under the receiver operating curve (AUROC) of 0.844 vs. 0.812 for AFP (p = 0.055) with a sensitivity of 95.2% and specificity of 47.1%; in detecting early HCC, AUROC of AFP/GP73 was 0. 804 vs. 0.766 for AFP (p = 0.086). sGP73 correlated with AST, AST/ALT, ALB, A/G and ALP in LC. The positive rate of sGP73 in angioma, FNH, ICC, and MC was 0, 50, 63.3, 53.3%, respectively; AFP/GP73 was 0.796 with the sensitivity of 81.4% and specificity of 70.0% when differentiating MC from AFP-negative HCC. Increased sGP73 is related to hepatic impairment and chronic fibrosis, and when combined with AFP could improve the differential diagnosis of hepatic diseases.
authors.affiliation: Department of Clinical Biochemistry, Chinese PLA General Hospital, 28 Fuxing Rd, Beijing, China.
authors.forename: Liyuan
authors.initials: L
authors.lastname: Tian
authors.forename: Yu
authors.initials: Y
authors.lastname: Wang
authors.forename: Dabin
authors.initials: D
authors.lastname: Xu
authors.forename: Junhao
authors.initials: J
authors.lastname: Gui
authors.forename: Xingwang
authors.initials: X
authors.lastname: Jia
authors.forename: Hongli
authors.initials: H
authors.lastname: Tong
authors.forename: Xinyu
authors.initials: X
authors.lastname: Wen
authors.forename: Zhennan
authors.initials: Z
authors.lastname: Dong
authors.forename: Yaping
authors.initials: Y
authors.lastname: Tian
mesh_terms: D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000097:blood*; D014408:Biomarkers, Tumor / Q000097:blood; D006528:Carcinoma, Hepatocellular / Q000097:blood*; D005260:Female; D006801:Humans; D008103:Liver Cirrhosis / Q000097:blood; D008107:Liver Diseases / Q000097:blood*; D008113:Liver Neoplasms / Q000097:blood*; D008297:Male; D008565:Membrane Proteins / Q000097:blood*; D008875:Middle Aged; D012680:Sensitivity and Specificity
chemical_list: D015415:Biomarkers; D014408:Biomarkers, Tumor; C410824:GOLM1 protein, human; D008565:Membrane Proteins